Abstract:Purpose: Metabolomics has attracted attention as a new method for understanding the molecular mechanisms of psychiatric disorders. Current metabolomics technology allows us to measure over hundreds of metabolites at a time and is a useful indicator of the consequences of complex and continuous changes in metabolic profiles due to the execution of genomic information and external factors of biological activity. Therefore, metabolomics is imperative to the discovery of biomarkers and mechanisms associated with pathophysiological processes. In this study, we investigated metabolites changes in hospitalized patients with chronic schizophrenia compared to that in healthy controls, and examined the correlations between the metabolites and psychiatric symptoms. Patients and Methods: Thirty patients with schizophrenia and ten healthy controls participated in this study between September 2019 and June 2020. The mean duration of disease in patients with schizophrenia was 26 years. Clinical and neuropsychiatric symptoms of patients with schizophrenia were assessed using the Positive and Negative Syndrome Scale (PANSS). Metabolomics was conducted using Capillary Electrophoresis Fourier Transform Mass Spectrometry (CE-FTMS), using serum samples from patients with schizophrenia and healthy controls. Metabolomics assigned a candidate compound to the 446 (cation 279, anion 167) peaks. Hierarchical cluster analysis (HCA), principal component analysis (PCA), logistic regression analysis, receiver operating characteristic (ROC) analysis, and linear regression analysis were used to analyze the metabolites changes, identifying the disease and the relationship between metabolites and psychiatric symptoms. Results: HCA showed that approximately 60% of metabolites had lower peak values in patients with schizophrenia than in healthy controls. Glutamate metabolism and the urea cycle had the highest proportions in the metabolic pathway, which decreased in patients with schizophrenia. PCA showed a clear separation between patients with schizophrenia and healthy controls in the first principal component (the contribution ratio of the first principal component was 15.9%). Logistic regression analysis suggested that the first principal component was a predictor of disease (odds = 1.36, 95%CI = 1.11–1.67, p = 0.0032). ROC analysis showed a sensitivity of 93% and a specificity of 100% for the diagnosis of schizophrenia with a cut-off value of the first principal component; −3.33 (AUC = 0.95). We extracted the high factor loading for the first principal component. Gamma-glutamyl-valine (γ-Glu-Val) was significantly negatively correlated with PANSS total scores ( r = −0.45, p = 0.012) and PANSS general scores ( r = −0.49, p = 0.0055). Gamma-glutamyl-phenylalanine (γ-Glu-Phe) was significantly negatively correlated with PANSS total score ( r = −0.40, p = 0.031) and PANSS general score ( r = −0.41, p = 0.025). Tetrahydrouridine was significantly positively correlated with PANSS negative scores ( r = 0.53, p = 0.0061). Conclusion: Metabolites changes in hospitalized patients with chronic schizophrenia showed extensive and generalized declines. Glutamate metabolism and the urea cycle had the highest proportions in the metabolic pathway, which decreased in the schizophrenia group. Metabolomic analysis was useful to identify chronic schizophrenia. Some glutamate compound metabolites had a relationship with psychiatric symptoms.

The Amino Acid Metabolism Pathway of Peripheral T Lymphocytes and Ketamine-Induced Schizophrenia-Like Phenotype

Metabolomic Analysis Reveals Metabolic Disturbance in the Cortex and Hippocampus of Subchronic Mk-801 Treated Rats

Comprehensive Metabolomic Characterization of the Hippocampus in a Ketamine Mouse Model of Schizophrenia.

Cortical Functional Hyperconnectivity in a Mouse Model of Depression and Selective Network Effects of Ketamine

Proteomic Characteristics of the Prefrontal Cortex and Hippocampus in Mice with Chronic Ketamine-Induced Anxiety and Cognitive Impairment

NMDA Receptor Hypofunction Induces Dysfunctions of Energy Metabolism and Semaphorin Signaling in Rats: a Synaptic Proteome Study.

Psychiatric Symptoms in Individuals Who Use Ketamine Versus Methamphetamine—implications for Glutamatergic and Dopaminergic Model for Schizophrenia: a Cohort Study

Higher Glutamatergic Activity in the Medial Prefrontal Cortex in Chronic Ketamine Users

The Immune Regulatory Mechanism of Ketamine-Induced Psychiatric Disorders: A New Perspective on Drug-Induced Psychiatric Symptoms

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a 1 H MRS study

Metabolite differences in the medial prefrontal cortex in schizophrenia patients with and without persistent auditory verbal hallucinations: a <SUP>1</SUP>H MRS study

Neuronal injury, but not microglia activation, is associated with ketamine-induced experimental schizophrenic model in mice.

Comparative metabolomic analysis in plasma and cerebrospinal fluid of humans and in plasma and brain of mice following antidepressant-dose ketamine administration

Exploring Metabolic Pathway Disruption in the Subchronic Phencyclidine Model of Schizophrenia with the Generalized Singular Value Decomposition

Schizophrenia Shows A Unique Metabolomics Signature in Plasma

Potential Benefits of Ketone Therapy as a Novel Immunometabolic Treatment for Schizophrenia

Alteration of lipids and amino acids in plasma distinguish schizophrenia patients from controls: A targeted metabolomics study

A Metabolomics Study of Serum in Hospitalized Patients With Chronic Schizophrenia

Reproducing the dopamine pathophysiology of schizophrenia and approaches to ameliorate it: a translational imaging study with ketamine

The association between Inflammation and Kynurenine Pathway Metabolites in Electroconvulsive Therapy for Schizophrenia: Implications for Clinical Efficacy

Potential metabolite markers of schizophrenia